Apollon Wealth Management LLC Has $244,000 Holdings in Smith & Nephew plc (NYSE:SNN)

Apollon Wealth Management LLC cut its stake in shares of Smith & Nephew plc (NYSE:SNN) by 13.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 7,832 shares of the medical equipment provider’s stock after selling 1,210 shares during the period. Apollon Wealth Management LLC’s holdings in Smith & Nephew were worth $244,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of SNN. Argonautica Private Wealth Management Inc. raised its position in Smith & Nephew by 6.3% during the second quarter. Argonautica Private Wealth Management Inc. now owns 10,244 shares of the medical equipment provider’s stock valued at $254,000 after purchasing an additional 605 shares in the last quarter. First Trust Direct Indexing L.P. grew its stake in shares of Smith & Nephew by 6.9% in the third quarter. First Trust Direct Indexing L.P. now owns 9,659 shares of the medical equipment provider’s stock worth $301,000 after purchasing an additional 626 shares during the last quarter. Inspire Advisors LLC grew its stake in shares of Smith & Nephew by 3.0% in the second quarter. Inspire Advisors LLC now owns 22,286 shares of the medical equipment provider’s stock worth $552,000 after purchasing an additional 639 shares during the last quarter. Rhumbline Advisers grew its stake in shares of Smith & Nephew by 8.6% in the second quarter. Rhumbline Advisers now owns 10,365 shares of the medical equipment provider’s stock worth $257,000 after purchasing an additional 819 shares during the last quarter. Finally, Janney Montgomery Scott LLC grew its stake in shares of Smith & Nephew by 13.8% in the first quarter. Janney Montgomery Scott LLC now owns 9,611 shares of the medical equipment provider’s stock worth $244,000 after purchasing an additional 1,165 shares during the last quarter. 25.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on SNN. StockNews.com lowered shares of Smith & Nephew from a “strong-buy” rating to a “buy” rating in a report on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft lowered shares of Smith & Nephew from a “buy” rating to a “hold” rating in a report on Friday, November 1st. Finally, Berenberg Bank lowered shares of Smith & Nephew from a “buy” rating to a “hold” rating in a report on Wednesday, November 6th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold”.

Smith & Nephew Price Performance

SNN opened at $25.54 on Tuesday. Smith & Nephew plc has a twelve month low of $23.65 and a twelve month high of $31.72. The company’s 50-day moving average price is $28.62 and its two-hundred day moving average price is $27.88. The company has a current ratio of 2.51, a quick ratio of 1.11 and a debt-to-equity ratio of 0.63.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.